United Historical Income Statement

UTHR Stock

USD 305.57 2.45 0.80%

Historical analysis of United Therapeutics income statement accounts such as Depreciation And Amortization of 76.1 M, Total Revenue of 3 B, Gross Profit of 2.7 B or Other Operating Expenses of 1.6 B can show how well United Therapeutics performed in making a profits. Evaluating United Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of United Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining United Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether United Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

About United Income Statement Analysis

United Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to United Therapeutics shareholders. The income statement also shows United investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

United Therapeutics Income Statement Chart

At this time, United Therapeutics' Total Operating Expenses is relatively stable compared to the past year. As of 03/28/2025, Income Before Tax is likely to grow to about 1.6 B, while Selling And Marketing Expenses is likely to drop slightly above 91.5 M.

Total Revenue Gross Profit Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts United Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of United Therapeutics minus its cost of goods sold. It is profit before United Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of United Therapeutics. It is also known as United Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from United Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Total Operating Expenses is relatively stable compared to the past year. As of 03/28/2025, Income Before Tax is likely to grow to about 1.6 B, while Selling And Marketing Expenses is likely to drop slightly above 91.5 M.

	2022	2023	2024	2025 (projected)
Gross Profit	1.8B	2.1B	2.6B	2.7B
Total Revenue	1.9B	2.3B	2.9B	3.0B

Gross Profit Total Revenue

United Therapeutics income statement Correlations

	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Interest Expense	Selling General Administrative	Cost Of Revenue	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.88	0.87	0.97	0.52	0.56	0.63	0.58	0.94	0.55	0.33	0.61	0.8	0.85	0.79	0.28	-0.55	0.59	0.0	-0.61	-0.62	0.76	0.7	0.84	0.8
Total Revenue	0.88		1.0	0.81	0.85	0.87	0.28	0.89	0.74	0.85	0.29	0.88	0.68	0.88	0.88	0.67	-0.56	0.86	-0.08	-0.68	-0.3	0.83	0.81	0.76	0.65
Gross Profit	0.87	1.0		0.81	0.85	0.87	0.28	0.89	0.74	0.86	0.29	0.87	0.65	0.87	0.85	0.68	-0.56	0.85	-0.05	-0.66	-0.31	0.8	0.78	0.75	0.64
Other Operating Expenses	0.97	0.81	0.81		0.39	0.43	0.74	0.46	0.99	0.42	0.31	0.48	0.79	0.81	0.75	0.19	-0.53	0.46	0.03	-0.56	-0.65	0.71	0.65	0.77	0.76
Operating Income	0.52	0.85	0.85	0.39		0.99	-0.23	0.99	0.28	0.98	0.24	0.97	0.37	0.67	0.73	0.87	-0.39	0.97	-0.13	-0.59	0.11	0.69	0.72	0.53	0.37
Ebit	0.56	0.87	0.87	0.43	0.99		-0.19	1.0	0.33	0.97	0.21	0.97	0.42	0.69	0.77	0.85	-0.37	0.96	-0.16	-0.63	0.08	0.74	0.77	0.58	0.4
Research Development	0.63	0.28	0.28	0.74	-0.23	-0.19		-0.16	0.81	-0.21	0.04	-0.15	0.54	0.28	0.22	-0.34	-0.35	-0.18	0.08	0.02	-0.8	0.19	0.09	0.44	0.58
Ebitda	0.58	0.89	0.89	0.46	0.99	1.0	-0.16		0.35	0.97	0.22	0.97	0.44	0.71	0.78	0.84	-0.38	0.97	-0.16	-0.64	0.05	0.76	0.78	0.6	0.42
Total Operating Expenses	0.94	0.74	0.74	0.99	0.28	0.33	0.81	0.35		0.32	0.3	0.38	0.74	0.76	0.64	0.12	-0.52	0.35	0.1	-0.48	-0.71	0.61	0.54	0.72	0.73
Income Before Tax	0.55	0.85	0.86	0.42	0.98	0.97	-0.21	0.97	0.32		0.4	0.99	0.38	0.71	0.73	0.89	-0.38	0.98	0.04	-0.62	0.11	0.72	0.75	0.55	0.36
Total Other Income Expense Net	0.33	0.29	0.29	0.31	0.24	0.21	0.04	0.22	0.3	0.4		0.42	0.23	0.44	0.26	0.3	-0.07	0.43	0.73	-0.39	0.04	0.4	0.43	0.32	0.15
Net Income	0.61	0.88	0.87	0.48	0.97	0.97	-0.15	0.97	0.38	0.99	0.42		0.47	0.74	0.79	0.81	-0.36	1.0	-0.01	-0.67	0.03	0.79	0.81	0.65	0.47
Interest Expense	0.8	0.68	0.65	0.79	0.37	0.42	0.54	0.44	0.74	0.38	0.23	0.47		0.63	0.78	0.07	-0.36	0.45	-0.2	-0.46	-0.45	0.81	0.73	0.77	0.71
Selling General Administrative	0.85	0.88	0.87	0.81	0.67	0.69	0.28	0.71	0.76	0.71	0.44	0.74	0.63		0.76	0.52	-0.58	0.71	0.11	-0.62	-0.25	0.7	0.69	0.74	0.57
Cost Of Revenue	0.79	0.88	0.85	0.75	0.73	0.77	0.22	0.78	0.64	0.73	0.26	0.79	0.78	0.76		0.44	-0.43	0.78	-0.27	-0.74	-0.21	0.91	0.91	0.74	0.64
Income Tax Expense	0.28	0.67	0.68	0.19	0.87	0.85	-0.34	0.84	0.12	0.89	0.3	0.81	0.07	0.52	0.44		-0.38	0.8	0.19	-0.42	0.34	0.43	0.47	0.21	-0.01
Selling And Marketing Expenses	-0.55	-0.56	-0.56	-0.53	-0.39	-0.37	-0.35	-0.38	-0.52	-0.38	-0.07	-0.36	-0.36	-0.58	-0.43	-0.38		-0.29	-0.09	0.08	0.23	-0.16	-0.13	-0.21	-0.26
Net Income From Continuing Ops	0.59	0.86	0.85	0.46	0.97	0.96	-0.18	0.97	0.35	0.98	0.43	1.0	0.45	0.71	0.78	0.8	-0.29		-0.02	-0.68	0.04	0.8	0.82	0.65	0.46
Non Operating Income Net Other	0.0	-0.08	-0.05	0.03	-0.13	-0.16	0.08	-0.16	0.1	0.04	0.73	-0.01	-0.2	0.11	-0.27	0.19	-0.09	-0.02		0.12	0.02	-0.18	-0.18	-0.11	-0.14
Discontinued Operations	-0.61	-0.68	-0.66	-0.56	-0.59	-0.63	0.02	-0.64	-0.48	-0.62	-0.39	-0.67	-0.46	-0.62	-0.74	-0.42	0.08	-0.68	0.12		0.11	-0.8	-0.85	-0.54	-0.36
Tax Provision	-0.62	-0.3	-0.31	-0.65	0.11	0.08	-0.8	0.05	-0.71	0.11	0.04	0.03	-0.45	-0.25	-0.21	0.34	0.23	0.04	0.02	0.11		-0.19	-0.09	-0.45	-0.78
Interest Income	0.76	0.83	0.8	0.71	0.69	0.74	0.19	0.76	0.61	0.72	0.4	0.79	0.81	0.7	0.91	0.43	-0.16	0.8	-0.18	-0.8	-0.19		0.99	0.82	0.62
Net Interest Income	0.7	0.81	0.78	0.65	0.72	0.77	0.09	0.78	0.54	0.75	0.43	0.81	0.73	0.69	0.91	0.47	-0.13	0.82	-0.18	-0.85	-0.09	0.99		0.77	0.54
Reconciled Depreciation	0.84	0.76	0.75	0.77	0.53	0.58	0.44	0.6	0.72	0.55	0.32	0.65	0.77	0.74	0.74	0.21	-0.21	0.65	-0.11	-0.54	-0.45	0.82	0.77		0.84
Extraordinary Items	0.8	0.65	0.64	0.76	0.37	0.4	0.58	0.42	0.73	0.36	0.15	0.47	0.71	0.57	0.64	-0.01	-0.26	0.46	-0.14	-0.36	-0.78	0.62	0.54	0.84

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.7

CDIOW

Cardio Diagnostics

Pair Corr

Moving against United Stock

0.59	LUCD	Lucid Diagnostics	Pair Corr
0.56	WM	Waste Management	Pair Corr
0.52	PG	Procter Gamble	Pair Corr
0.33	GE	GE Aerospace	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

United Historical Income Statement

About United Income Statement Analysis

United Therapeutics Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

United Therapeutics income statement Correlations

United Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with United Therapeutics

Moving together with United Stock

Moving against United Stock

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Total Operating Expenses	+ 0.99	Other Operating Expenses
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income

Net Interest Income	- 0.85	Discontinued Operations
Interest Income	- 0.8	Discontinued Operations
Tax Provision	- 0.8	Research Development
Extraordinary Items	- 0.78	Tax Provision
Discontinued Operations	- 0.74	Cost Of Revenue
Tax Provision	- 0.71	Total Operating Expenses